Prometic Bioproduction Inc. company information, Employees & Contact Information

YIMMUGO® Now Available in the U.S.: Kedrion Biopharma Commercializes a New Ig Therapy for PI Yahoo Finance

Advanced Infusion Care (AIC) Now Offers Kedrion Biopharma’s YIMMUGO Business Wire

Kedrion Biopharma Receives Orphan Drug Designation for COAGADEX® for Acquired Factor X Deficiency (aFXD) and Starts Clinical Trial to Evaluate Efficacy and Safety PR Newswire

FDA Grants Approval for Kedrion Biopharma’s Primary Humoral Immunodeficiency Treatment Qivigy Pharmaceutical Executive

How JAGGAER is Simplifying Procurement for Kedrion Procurement Magazine

JAGGAER Streamlines Global Procurement for Kedrion Healthcare Digital

Kedrion receives FDA Orphan Drug Designation for investigational plasma-derived treatment for Congenital Aceruloplasminemia PR Newswire

Kedrion Raises Awareness Around Plasminogen Deficiency PR Newswire

Kedrion Biopharma Receives FDA Approval for QIVIGY® (Immune Globulin 10% IV) for treatment of Primary Humoral Immunodeficiency in Adults and confirms its plan to increase investments in the U.S. throughout its global operations. BioSpace

Kedrion Expands Ryplazim Distribution Network for PLGD-1 Patients PR Newswire

FDA Approves Kedrion's Bolognana Facility for Production of First and Only Treatment for PLGD-1, Ryplazim BioSpace

Kedrion Biopharma closes 2024 with a growth of +10% and unveils its new identity PR Newswire

Kedrion Biopharma's Focus on Advancing Patient Care in Rare Disease to be Showcased at NBDF Conference 2024 PR Newswire

Kedrion and Biotest complete long-term Exclusive Distribution Agreement for Yimmugo® in the US PR Newswire

Kedrion Announces Rare Disease Medicine RYPLAZIM® Now Available in US PR Newswire

Kedrion strengthens its network of plasma collection centers PR Newswire

KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB® PR Newswire

Kedrion reports a 15% Ebitda on €660.4m of revenues in 2021 PR Newswire

Kedrion Biopharma grows in North America as it completes acquisition of Prometic PR Newswire

Permira Funds and the Marcucci family complete investment in Kedrion and BPL and announce appointment of Ugo Di Francesco as CEO PR Newswire

Kedrion's global portfolio expands to China to supply human Albumin PR Newswire

First Patient Enrolled in KIDCARES10, Kedrion Biopharma Pediatric Primary Immunodeficiency Study PR Newswire

Icon Plc’s New Study on Kedrion IVIg 10% for Chronic ITP: What Investors Need to Know TipRanks

Kedrion Biopharma to commercialize RYPLAZIM® (plasminogen, human-tvmh) in U.S. to address unmet need in patients with ultra-rare condition: Plasminogen Deficiency Type 1 PR Newswire

Kedrion Names Val Romberg As CEO PR Newswire

First Patient Treated in KIDCARES10, Kedrion Biopharma Pediatric Primary Immunodeficiency Study PR Newswire

Kedrion Biopharma Phase III Trial, CARES10, achieves important milestone: Last Patient Treated PR Newswire

Private Equity Firm Permira Is Making a Big Bet on Blood Plasma With New Deals Bloomberg.com

Permira creates major blood plasma products player with Kedrion, BPL acquisitions Private Equity Insights

Permira and Marcucci family complete purchase and combination of Kedrion and BPL pehub.com

It’s official, Permira strikes control of leading plasma derivatives maker Kedrion and British competitor BPL. Together with ADIA. The Marcucci family and FSI fund to reinvest in the deal. Cdp Equity takes a call option – BeBeez International BeBeez International

Italian Kedrion plans to launch production of a unique medical remedy in Tashkent Kun.uz

Kedrion Biopharma refutes the news regarding the upcoming construction of a plant in the Tashkent region Kun.uz